<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874129</url>
  </required_header>
  <id_info>
    <org_study_id>YYPCT_YYC506_102</org_study_id>
    <nct_id>NCT04874129</nct_id>
  </id_info>
  <brief_title>Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506</brief_title>
  <official_title>Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant&#xD;
      administration of YYC506-T and YYC506-A&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 to evaluate the safety and pharmacokinetics characteristics between YYC506 and&#xD;
      concomitant administration of YYC506-T and YYC506-A. Which is designed as ramdomized, oral,&#xD;
      single dose, two-way crossover.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>ramdomized, open-label, single-dose, two-way crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters: Cmax</measure>
    <time_frame>Until 48 hours</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters: AUC</measure>
    <time_frame>Until 48 hours</time_frame>
    <description>YYC506-T, YYC506-A, YYC506 AUC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two-way Crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two-way Crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYC506-T and YYC506-A (phase 1)</intervention_name>
    <description>Comparator</description>
    <arm_group_label>A Group</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYC506 (phase 1)</intervention_name>
    <description>Test</description>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYC506-T and YYC506-A (phase 2)</intervention_name>
    <description>Comparator</description>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYC506 (phase 2)</intervention_name>
    <description>Test</description>
    <arm_group_label>A Group</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 19 ages healthy men&#xD;
&#xD;
          -  Over 50.0kg, 18.0kg/m2 ≤ BMI ≤ 30.0kg/m2&#xD;
&#xD;
          -  Men who don't have congenital disease and other cronic disease need to be cared. etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN)&#xD;
&#xD;
          -  Men who have drunken or eatten something including caffeine within 24 hours before.&#xD;
             etc.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Kyu Park, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chungbuk National University Hosipital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National Unviersity Hosipital</name>
      <address>
        <city>Cheongju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

